ReviewMedical oncology (Northwood, London, England)2014
Biomarkers in prostate cancer: new era and prospective.
Review in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel, Switzerland) · 2021Review
- Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.Investigative and clinical urology · 2021Article
- Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer.Cancer research and treatment · 2019Article
- Specific and reliable detection of Myosin 1C isoform A by RTqPCR in prostate cancer cells.PeerJ · 2018Article
- Focal Ablation of Prostate Cancer.Reviews in urology · 2018Article
- Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen.Electrochimica acta · 2017Article
- Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.International journal of molecular sciences · 2017Article
- LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Epigenetics · 2017Article
- Glycogen synthase kinase-3: a potential preventive target for prostate cancer management.Urologic oncology · 2015Review
- Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, most men are diagnosed with prostate cancer (PCa) after a prostate-specific antigen (PSA) test shows an elevated level of the PSA protein. An elevated level suggests cancer may be present. If an elevation is detected, a biopsy to detect cancer is followed. But the PSA test is controversial. An elevated level does not always mean there is cancer present. The test often leads men to having unnecessary biopsies and treatments. Even if cancer is found on biopsy, many of these cancers are slow growing and would not impact the lives of the men who have them. Current advances in molecular techniques have provided new tools facilitating the discovery of new biomarkers for PCa. The purpose of this review is to examine the advances in PCa biomarkers and implication for possible improving disease outcome. The future of cancer prognosis may rely on small panels of markers that can accurately predict PCa presence, stage, and metastasis and can serve as prognosticators, targets, and/or surrogate endpoints of disease progression and response to therapy.
Indexed as
Identifiers
25048724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.